FDA Expands Approval of Osimertinib in Lung Cancer

Published Date: 30 Sep 2024

EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In breast-conserving surgery, is micro-CT a useful tool for determining tumor margins?

2.

Report reveals lung cancer is the leading cause of cancer deaths in Florida

3.

FDA Expands Approval of Osimertinib in Lung Cancer

4.

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

5.

Venetoclax Combo Shows Promise in Younger Patients With AML


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot